Protective treatment for Covid-19 makes minimal impact
Limited uptake of antibody combination for vulnerable patients, while demand for antivirals seems to be slowing
There is limited uptake of Covid-19 treatments targeted at immunocompromised people and those who aren’t responsive to Covid-19 vaccines, largely for reasons that remain unclear. Meanwhile, demand for antivirals appears to be slowing, even as manufacturing capacity ramps up.